Prodrugs-from serendipity to rational design

Pharmacological Reviews

Volumn 63, Issue 3, 2011, Pages 750-771

  Huttunen, Kristiina M ^a   Raunio, Hannu ^a   Rautio, Jarkko ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ACETYLSALICYLIC ACID; ADEFOVIR; AMPRENAVIR; BAMBUTEROL; BIMATOPROST; CLOPIDOGREL; DABIGATRAN ETEXILATE; DIPIVEFRINE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ESOMEPRAZOLE; FENOFIBRATE; FOSAMPRENAVIR; FOSPHENYTOIN SODIUM; LANSOPRAZOLE; LATANOPROST; LISDEXAMFETAMINE; MB 07133; MIDODRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLMESARTAN; OSELTAMIVIR; PANTOPRAZOLE; PHENYTOIN; PR 104; PREDNISOLONE; PREDNISOLONE SODIUM PHOSPHATE; PRODRUG; R 130964; RABEPRAZOLE; SULFAMIDOCHRYSOIDINE; SULFANILAMIDE; TAZAROTENE; TIRAPAZAMINE; TRAVOPROST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR;

ACNE; ARTICLE; BIOTRANSFORMATION; CATALYSIS; COMPETITIVE INHIBITION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; GLAUCOMA; HUMAN; HYDROLYSIS; INFLUENZA A; INFLUENZA B; INJECTION SITE IRRITATION; LIPOPHILICITY; LIVER TOXICITY; MEMBRANE PERMEABILITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS; STROKE; UNSPECIFIED SIDE EFFECT;

ANIMALS; BIOTRANSFORMATION; DRUG DESIGN; DRUG DISCOVERY; DRUG TOXICITY; HUMANS; PRODRUGS; TECHNOLOGY, PHARMACEUTICAL;

EID: 79960671231     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.110.003459     Document Type: Article

References (134)

1. Albert A (1958) Chemical aspects of selective toxicity. Nature 182: 421-422.
2. Anderson RF, Shinde SS, Hay MP, Gamage SA, and Denny WA (2003) Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J Am Chem Soc 125: 748-756.
3. Bai JPF, Pacanowski M, Rahman A and Lesko LL (2010) The impact of pharmacogenetics on the clinical outcomes of prodrugs, in Prodrugs and Targeted Delivery: Towards Better ADME Properties (Rautio J ed) pp 453-481, Wiley-VCH Verlag GmbH & Co.
4. KGa A, Weinheim. Balimane PV, Tamai I, Guo A, Nakanishi T, Kitada H, Leibach FH, Tsuji A, and Sinko PJ (1998) Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun 250: 246-251.
5. Beaumont K, Webster R, Gardner I, and Dack K (2003) Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab 4: 461-485.
6. Bellott R, Le Morvan V, Charasson V, Laurand A, Colotte M, Zanger UM, Klein K, Smith D, Bonnet J, and Robert J (2008) Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene. Cancer Chemother Pharmacol 61: 481-488.
7. Bentley R (2009) Different roads to discovery; Prontosil (hence sulfa drugs) and penicillin (hence beta-lactams). J Ind Microbiol Biotechnol 36: 775-786.
8. Benzaria S, Pélicano H, Johnson R, Maury G, Imbach JL, Aubertin AM, Obert G, and Gosselin G (1996) Synthesis, in vitro antiviral evaluation, and stability studies of bis-(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. J Med Chem 39: 4958-4965.
9. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, and Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36: 386-399.
10. Boucher BA (1996) Fosphenytoin: a novel phenytoin prodrug. Pharmacotherapy 16: 777-791.
11. Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, Waldmann C, Schmalz HG, ten Berg JM, and Taubert D (2011) Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 17: 110-116.
12. Boyer SH, Sun Z, Jiang H, Esterbrook J, Gómez-Galeno JE, Craigo W, Reddy KR, Ugarkar BG, MacKenna DA, and Erion MD (2006) Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-β-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma. J Med Chem 49: 7711-7720.
13. Brauch H and Jordan VC (2009) Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach? Eur J Cancer 45: 2274-2283.
14. Browne TR, Kugler AR, and Eldon MA (1996) Pharmacology and pharmacokinetics of fosphenytoin. Neurology 46: S3-7.
15. Burnette TC, Harrington JA, Reardon JE, Merrill BM, and de Miranda P (1995) Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir. J Biol Chem 270: 15827-15831.
16. Chan OH and Stewart BH (1996) Physicochemical and drug-delivery considerations for oral drug bioavailability. Drug Discov Today 1: 461-473.
17. Chapman TM, Plosker GL, and Perry CM (2004) Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs 64: 2101-2124.
18. Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, and Koren G (2009) Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med 361: 827-828.
19. Cowen RL, Williams KJ, Chinje EC, Jaffar M, Sheppard FC, Telfer BA, Wind NS, and Stratford IJ (2004) Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res 64: 1396-1402.
20. Cruz DN (2000) Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension. Expert Opin Pharmacother 1: 835-840.
21. Dando T and Plosker G (2003) Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 63: 2215-2234.
22. Darby G (1993) The acyclovir legacy: its contribution to antiviral drug discovery. J Med Virol Suppl 1: 134-138.
23. del Amo EM, Urtti A, and Yliperttula M (2008) Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 35: 161-174.
24. Delahoy PJ, Magliano DJ, Webb K, Grobler M, and Liew D (2009) The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther 31: 236-244.
25. Denny WA (2001) Prodrug strategies in cancer therapy. Eur J Med Chem 36: 577-595.
26. Denny WA (2010) Hypoxia-activated prodrugs in cancer therapy: progress to the clinic. Future Oncol 6: 419-428.
27. Di L and Kerns EH (2007) Solubility issues in early discovery and HTS, in Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics (Augustijins P and Brewster M eds) pp 111-136, Springer Science + Business Media, New York.
28. Dobson PD and Kell DB (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 7: 205-220.
29. Duvvuri S, Majumdar S, and Mitra AK (2003) Drug delivery to the retina: challenges and opportunities. Expert Opin Biol Ther 3: 45-56.
30. Duvvuri S, Majumdar S, and Mitra AK (2004) Role of metabolism in ocular drug delivery. Curr Drug Metab 5: 507-515.
31. Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, and van Ryn J (2010) Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 30: 1885-1889.
32. Elion GB (1983) The biochemistry and mechanism of action of acyclovir. J Antimicrob Chemother 12 Suppl B: 9-17.
33. Ellis KJ, Stouffer GA, McLeod HL, and Lee CR (2009) Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics 10: 1799.
34. Erion MD, Bullough DA, Lin CC, and Hong Z (2006) HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver. Curr Opin Investig Drugs 7: 109-117.
35. Erion MD, Reddy KR, Boyer SH, Matelich MC, Gomez-Galeno J, Lemus RH, Ugarkar BG, Colby TJ, Schanzer J, and Van Poelje PD (2004) Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (Hep-Direct prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J Am Chem Soc 126: 5154-5163.
36. Erion MD, van Poelje PD, Mackenna DA, Colby TJ, Montag AC, Fujitaki JM, Linemeyer DL, and Bullough DA (2005) Liver-targeted drug delivery using Hep-Direct prodrugs. J Pharmacol Exp Ther 312: 554-560.
37. Ettmayer P, Amidon GL, Clement B, and Testa B (2004) Lessons learned from marketed and investigational prodrugs. J Med Chem 47: 2393-2404.
38. Fang JY and Leu YL (2006) Prodrug strategy for enhancing drug delivery via skin. Curr Drug Discov Technol 3: 211-224.
39. Farid NA, Kurihara A, and Wrighton SA (2010) Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 50: 126-142.
40. Fitzsimmons SA, Lewis AD, Riley RJ, and Workman P (1994) Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNAdamaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. Carcinogenesis 15: 1503-1510.
41. Fleisher D, Bong R, and Stewart BH (1996) Improved oral drug delivery: solubility limitations overcome by the use of prodrugs. Adv Drug Deliv Rev 19: 115-130.
42. Foster RH, Brogden RN, and Benfield P (1998) Tazarotene. Drugs 55: 705-711; discussion 712.
43. Furfine ES, Baker CT, Hale MR, Reynolds DJ, Salisbury JA, Searle AD, Studenberg SD, Todd D, Tung RD, and Spaltenstein A (2004) Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother 48: 791-798.
44. 0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord 5: 357-364.
45. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, and Desmeules J (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351: 2827-2831.
46. Giraud B, Hebert G, Deroussent A, Veal GJ, Vassal G, and Paci A (2010) Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opin Drug Metab Toxicol 6: 919-938.
47. Gonzalez FJ and Tukey RH (2006) Drug metabolism, in Goodman and Gilman's The Pharmacological Basis of Therapeutics (Brunton LL, Lazo JS, and Parker KL eds) pp 71-91, The McGraw-Hill Companies, Inc., New York.
48. Granero GE and Amidon GL (2006) Stability of valacyclovir: implications for its oral bioavailability. Int J Pharm 317: 14-18.
49. Gruer PJ, Vega JM, Mercuri MF, Dobrinska MR, and Tobert JA (1999) Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 84: 811-815.
50. Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, et al. (2010) The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res 70: 1573-1584.
51. Guise CP, Wang AT, Theil A, Bridewell DJ, Wilson WR, and Patterson AV (2007) Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol 74: 810-820.
52. Hellberg MR, Ke TL, Haggard K, Klimko PG, Dean TR, and Graff G (2003) The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2alpha by human and rabbit ocular tissue. J Ocul Pharmacol Ther 19: 97-103.
53. Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, and Wilson WR (2007) Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int J Radiat Oncol Biol Phys 69: 560-571.
54. Society for Cardiovascular Angiography and Interventions, Society of Thoracic Sur-geons, Writing Committee Members, Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, and Stein CM (2010) ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 122: 537-557.
55. Hornykiewicz O (2010) A brief history of levodopa. J Neurol 257 (Suppl 2): S249-S252.
56. Hörter D and Dressman JB (2001) Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 46: 75-87.
57. Hughes B (2010) First oral warfarin alternative approved in the US. Nat Rev Drug Discov 9: 903-906.
58. Hussain A and Truelove JE (1976) Prodrug approaches to enhancement of physicochemical properties of drugs IV: novel epinephrine prodrug. J Pharm Sci 65: 1510-1512.
59. Huttunen KM, Mähönen N, Raunio H, and Rautio J (2008) Cytochrome P450-activated prodrugs: targeted drug delivery. Curr Med Chem 15: 2346-2365.
60. Imai T (2006) Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet 21: 173-185.
61. Imai T, Imoto M, Sakamoto H, and Hashimoto M (2005) Identification of esterases expressed in Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption. Drug Metab Dispos 33: 1185-1190.
62. Inturrisi CE, Schultz M, Shin S, Umans JG, Angel L, and Simon EJ (1983) Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci 33: 773-776.
63. Jordan VC (2007) New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 72: 829-842.
64. Kaback MB, Podos SM, Harbin TS, Jr., Mandell A, and Becker B (1976) The effects of dipivalyl epinephrine on the eye. Am J Ophthalmol 81: 768-772.
65. Kaukonen KM, Olkkola KT, and Neuvonen PJ (1998) Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 53: 445-449.
66. Khor SP and Hsu A (2007) The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. Curr Clin Pharmacol 2: 234-243.
67. Kobayashi M, Takagi M, Fukumoto K, Kato R, Tanaka K, and Ueno K (2008) The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. Drug Metab Pharmacokinet 23: 115-119.
68. Kohn AN, Moss AP, Hargett NA, Ritch R, Smith H Jr, and Podos SM (1979) Clinical comparison of dipivalyl epinephrine and epinephrine in the treatment of glaucoma. Am J Ophthalmol 87: 196-201.
69. Krämer SD and Testa B (2008) The biochemistry of drug metabolism-an introduction: part 6. Inter-individual factors affecting drug metabolism. Chem Biodivers 5: 2465-2578.
70. Krise JP and Stella VJ (1996) Prodrugs of phosphates, phosphonates, and phosphinates. Adv Drug Deliv Rev 19: 287-310.
71. Leenders RG, Damen EW, Bijsterveld EJ, Scheeren HW, Houba PH, van der Meulen-Muileman IH, Boven E, and Haisma HJ (1999) Novel anthracycline-spacer-β-glucuronide,-β-glucoside, and-β-galactoside prodrugs for application in selective chemotherapy. Bioorg Med Chem 7: 1597-1610.
72. Liederer BM and Borchardt RT (2006) Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci 95: 1177-1195.
73. Lloyd RV, Duling DR, Rumyantseva GV, Mason RP, and Bridson PK (1991) Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. Mol Pharmacol 40: 440-445.
74. MacKenna DA, Montag A, Boyer SH, Linemeyer DL, and Erion MD (2009) Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma. Cancer Chemother Pharmacol 64: 981-991.
75. Majumdar S, Duvvuri S, and Mitra AK (2004) Membrane transporter/receptortargeted prodrug design: strategies for human and veterinary drug development. Adv Drug Deliv Rev 56: 1437-1452.
76. Mandell AI, Stentz F, and Kitabchi AE (1978) Dipivalyl epinephrine: a new pro-drug in the treatment of glaucoma. Ophthalmology 85: 268-275.
77. McClellan K and Perry CM (2001) Oseltamivir: a review of its use in influenza. Drugs 61: 263-283.
78. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, et al. (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304: 1821-1830.
79. Missaghi S, Young C, Fegely K, and Rajabi-Siahboomi AR (2010) Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies. Drug Dev Ind Pharm 36: 180-189.
80. Müller CE (2009) Prodrug approaches for enhancing the bioavailability of drugs with low solubility. Chem Biodivers 6: 2071-2083.
81. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, et al. (2001) Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132: 472-484.
82. Neuvonen PJ (2010) Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs 11: 323-332.
83. Neuvonen PJ, Backman JT, and Niemi M (2008) Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 47: 463-474.
84. Noble S and Goa KL (1999) Adefovir dipivoxil. Drugs 58: 479-487.
85. Papot S, Tranoy I, Tillequin F, Florent JC, and Gesson JP (2002) Design of selectively activated anticancer prodrugs: elimination and cyclization strategies. Curr Med Chem Anticancer Agents 2: 155-185.
86. Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL, and Stratford IJ (1995) Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 72: 1144-1150.
87. Persson G, Pahlm O, and Gnosspelius Y (1995) Oral bambuterol versus terbutaline in patients with asthma. Curr Ther Res 56: 457-465.
88. Pinto N, Ludeman SM, and Dolan ME (2009) Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics 10: 1897-1903.
89. Rautio J (2010) Prodrug strategies in drug design, in Prodrugs and Targeted Delivery: Towards Better ADME Properties (Rautio J ed) pp 1-30, Wiley-VCH Verlag GmbH & Co.
90. KGaA, Weinheim. Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Järvinen T, and Savolainen J (2008) Prodrugs: design and clinical applications. Nat Rev Drug Discov 7: 255-270.
91. Reddy KR, Colby TJ, Fujitaki JM, van Poelje PD, and Erion MD (2005) Liver targeting of hepatitis-B antiviral lamivudine using the HepDirect prodrug technology. Nucleosides Nucleotides Nucleic Acids 24: 375-381.
92. + ATPase. Annu Rev Pharmacol Toxicol 35: 277-305.
93. Satoh T and Hosokawa M (2006) Structure, function and regulation of carboxylesterases. Chem Biol Interact 162: 195-211.
94. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, and La Du BN (2002) Current progress on esterases: from molecular structure to function. Drug Metab Dispos 30: 488-493.
95. Sawynok J (1986) The therapeutic use of heroin: a review of the pharmacological literature. Can J Physiol Pharmacol 64: 1-6.
96. Sekino K, Kubota T, Okada Y, Yamada Y, Yamamoto K, Horiuchi R, Kimura K, and Iga T (2003) Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 59: 589-592.
97. Shanghag A, Yam N and Jasti B (2006) Prodrugs as drug delivery systems, in Design of Controlled Release Drug Delivery Systems (Li X and Jasti BR eds) pp 75-106, The McGraw-Hill Company, Inc., New York.
98. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, and Yan B (2006) Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 319: 1477-1484.
99. +)-ATPase by proton pump inhibitors. J Am Chem Soc 126: 7800-7811.
100. Sica DA, Gehr TW, and Ghosh S (2005) Clinical pharmacokinetics of losartan. Clin Pharmacokinet 44: 797-814.
101. Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, Weinshilboum RM, Hawse JR, Spelsberg TC, and Goetz MP (2010) Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 28: 2768-2776.
102. Sinko PJ and Balimane PV (1998) Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats. Biopharm Drug Dispos 19: 209-217.
103. Sitar DS (1996) Clinical pharmacokinetics of bambuterol. Clin Pharmacokinet 31: 246-256.
104. Sloan KB and Wasdo S (2003) Designing for topical delivery: prodrugs can make the difference. Med Res Rev 23: 763-793.
105. Sloan KB, Wasdo SC, and Rautio J (2006) Design for optimized topical delivery: prodrugs and a paradigm change. Pharm Res 23: 2729-2747.
106. Smith HS (2009) Opioid metabolism. Mayo Clin Proc 84: 613-624.
107. Sorbera LA, Bayes M, Castaner J, and Silvestre J (2001) Melagatran and ximelagatran: anticoagulant thrombin inhibitor. Drugs Future 26: 1155-1170.
108. Stamer UM, Zhang L, and Stüber F (2010) Personalized therapy in pain management: where do we stand? Pharmacogenomics 11: 843-864.
109. Stangier J, Rathgen K, Stähle H, Gansser D, and Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64: 292-303.
110. Stella VJ (2010) Prodrugs: Some thoughts and current issues. J Pharm Sci 99: 4755-4765.
111. Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H and Tilley JW (2007) Prodrugs: Challenges and Rewards Part 1 & 2, Springer Science + Business Media, New York.
112. Stella VJ and Nti-Addae KW (2007) Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev 59: 677-694.
113. Susanna R, Jr., Chew P, and Kitazawa Y (2002) Current status of prostaglandin therapy: latanoprost and unoprostone. Surv Ophthalmol 47 (Suppl 1): S97-104.
114. Svensson LA and Tunek A (1988) The design and bioactivation of presystemically stable prodrugs. Drug Metab Rev 19: 165-194.
115. Taylor MD (1996) Improved passive oral drug delivery via prodrugs. Adv Drug Deliv Rev 19: 131-148.
116. Testa B (2004) Prodrug research: futile or fertile? Biochem Pharmacol 68: 2097-2106.
117. Testa B and Krämer SD (2007) The biochemistry of drug metabolism-an introduction: Part 2. Redox reactions and their enzymes. Chem Biodivers 4: 257-405.
118. Testa B, and Mayer JM (2003) Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology, VHCA Verlag Helvetica Chimica Acta AG, Zürich, and Wiley-VCR GmbH & Vo. KGaA, Weinheim.
119. Tillmann HL (2007) Pradefovir, a liver-targeted prodrug of adefovir against HBV infection. Curr Opin Investig Drugs 8: 682-690.
120. Timmins GS and Deretic V (2006) Mechanisms of action of isoniazid. Mol Microbiol 62: 1220-1227.
121. Tirkkonen T and Laine K (2004) Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. Clin Pharmacol Ther 76: 639-647.
122. Tirkkonen T, Ryynänen A, Vahlberg T, Irjala K, Klaukka T, Huupponen R, and Laine K (2008) Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study. Drug Saf 31: 231-240.
123. Tsuda M, Terada T, Irie M, Katsura T, Niida A, Tomita K, Fujii N, and Inui K (2006) Transport characteristics of a novel peptide transporter 1 substrate, antihypoten-sive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther 318: 455-460.
124. 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro. Biochem Pharmacol 37: 3867-3876.
125. Unadkat JD and Rowland M (1985) Pharmacokinetics of prednisone and prednisolone at steady state in the rabbit. Drug Metab Dispos 13: 503-509.
126. United States Food and Drug Administration (2006) Summary minutes of the Advisory Committee for Pharmaceutical Science, Clinical Pharmacology Subcommittee. 18-19 October. Available at: http://www.fda.gov/ohrms/dockets/ac/06/minutes/2006-4248m1.pdf.
127. van De Waterbeemd H, Smith DA, Beaumont K, and Walker DK (2001) Propertybased design: optimization of drug absorption and pharmacokinetics. J Med Chem 44: 1313-1333.
128. Vane JR and Botting RM (2003) The mechanism of action of aspirin. Thromb Res 110: 255-258.
129. Voronov P, Przybylo HJ, and Jagannathan N (2007) Apnea in a child after oral codeine: a genetic variant-an ultra-rapid metabolizer. Paediatr Anaesth 17: 684-687.
130. Wallentin L (2009) P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 30: 1964-1977.
131. Wathion N (2009) Public statement on possible interaction between clopidogrel and proton pump inhibitors. EMEA/328956/2009. European Medicines Agency, London. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500014409.pdf
132. Wire MB, Shelton MJ, and Studenberg S (2006) Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 45: 137-168.
133. Yan YD, Kim HK, Seo KH, Lee WS, Lee GS, Woo JS, Yong CS, and Choi HG (2010) The physicochemical properties, in vitro metabolism and pharmacokinetics of a novel ester prodrug of EXP3174. Mol Pharm 7: 2132-2140.
134. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, and Lee WW (1986) SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12: 1239-1242.